Literature DB >> 1355156

Splenic lymphoma with villous lymphocytes in tropical West Africa.

I Bates1, G Bedu-Addo, T Rutherford, D H Bevan.   

Abstract

Splenic lymphoma with villous lymphocytes (SLVL) is a monoclonal B-lymphoproliferative disorder characterised by splenomegaly and distinctive villous lymphocytes in the peripheral blood. It has not previously been reported from Africa, but we describe ten Ghanaian patients with SLVL seen at one hospital during a 4-year period. The clinical presentation is similar in Africa and in temperate regions, though the lymphocyte count is higher in African patients and the disorder predominantly affects middle-aged women rather than elderly men. It is likely that SLVL has previously been classified as splenic chronic lymphocytic leukaemia or hyper-reactive malarial splenomegaly.

Entities:  

Mesh:

Year:  1992        PMID: 1355156     DOI: 10.1016/0140-6736(92)92108-r

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  3 in total

1.  Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma.

Authors:  Gunhild Trøen; Vigdis Nygaard; Tor-Kristian Jenssen; Ida Münster Ikonomou; Anne Tierens; Estella Matutes; Alicja Gruszka-Westwood; Daniel Catovsky; Ola Myklebost; Grete Lauritzsen; Eivind Hovig; Jan Delabie
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

2.  Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations.

Authors:  Anne Tierens; Jan Delabie; Agnieszka Malecka; Junbai Wang; Alicja Gruszka-Westwood; Daniel Catovsky; Estella Matutes
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

Review 3.  Outline for writing an article for current treatment options in oncology: splenic lymphoma with villous lymphocytes.

Authors:  Xavier Troussard; Edouard Cornet
Journal:  Curr Treat Options Oncol       Date:  2007-04
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.